HERBERT B SLADE
Medical Practice in Saint Paul, MN
License number
Pennsylvania MD041644L
Category
Medicine
Type
Medical Physician and Surgeon
Address
Address
2
Saint Paul, MN 55144
Pennsylvania
Pennsylvania
Personal information
See more information about HERBERT B SLADE at radaris.comName
Address
Phone
1536 Shannon Ct, Woodbury, MN 55125
1784 Selby Ave, Saint Paul, MN 55104
Minneapolis, MN
Professional information
Method For The Treatment Of Dermal Lesions Caused By Envenomation
US Patent:
2002001, Feb 7, 2002
Filed:
Mar 29, 2001
Appl. No.:
09/820420
Inventors:
Herbert Slade - Woodbury MN, US
International Classification:
A61K031/4745
US Classification:
514/292000, 514/293000
Abstract:
A method of treating dermal lesions caused by envenomation comprising applying a therapeutically effective amount of an immune response modifier compound selected from the group consisting of imidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, imidazonaphthyridine amines, tetrahydroimidazonaphthyridine amines, oxazolopyridine amines, oxazoloquinoline amines, thiazolopyridine amines, thiazoloquinoline amines and 1,2-bridged imidazoquinoline amines to the site of the lesion is disclosed.
Methods And Packages To Enhance Safety When Using Imiquimod To Treat Children Diagnosed With Skin Disorders
US Patent:
2008028, Nov 13, 2008
Filed:
Mar 24, 2008
Appl. No.:
12/054357
Inventors:
Herbert B. Slade - Woodbury MN, US
James H. Lee - Devon PA, US
James H. Lee - Devon PA, US
International Classification:
A61K 31/437, A61P 17/00
US Classification:
514292
Abstract:
Pharmaceutical packages and methods for enhancing the safety of imiquimod when used to treat children affected by skin disorders are disclosed. More particularly, the safety profile of imiquimod use is enhanced by providing information to the children, guardians of the children, including parents and health care professionals, that systemic absorption of imiquimod and other effects may be observed when imiquimod therapy is used to treat children of between about 2 and about 12 years of age. Examples of systemic absorption include a serum imiquimod concentrations of less than about 2 ng/mL, a decrease in median white blood cell count by about 1.4*10/L or a decrease in median absolute neutrophil count by about 1.42*10/L. Topical and/or transdermal delivery of imiquimod, including creams, ointments, gels, lotions, salves and pressure-sensitive adhesive compositions to treat dermatological disorders in children, namely, molluscum contagiosum, viral infections, such as Type I or Type II Herpes simplex infections and condyloma acuminata, genital warts and perianal warts, actinic keratosis and superficial basal cell carcinoma, and to induce interferon biosynthesis, are disclosed.
Multi-Route Administration Of Immune Response Modifier Compounds
US Patent:
2008011, May 22, 2008
Filed:
Dec 28, 2005
Appl. No.:
11/722585
Inventors:
Herbert B. Slade - Woodbury MN, US
Cynthia A. Guy - Osseo MN, US
Cynthia A. Guy - Osseo MN, US
Assignee:
3M INNOVATIVE PROPERTIES COMPANY - St. Paul MN
International Classification:
A61K 31/4745, A61P 35/00, A61P 31/00
US Classification:
514293
Abstract:
A method of treating disease with immune response modifier (IRM) compounds by using at least two different routes of administration, such as administering at least one IRM to a subject locally (e.g., topically) at a disease site in combination with separately administering at least one IRM to the subject systemically (e.g., orally or by injection).
Compositions And Methods For Induction Of Opioid Receptors
US Patent:
2004021, Oct 28, 2004
Filed:
Apr 27, 2004
Appl. No.:
10/832737
Inventors:
Woubalem Birmachu - St. Anthony Village MN, US
Herbert Slade - Woodbury MN, US
John Stolpa - St. Paul MN, US
Mirjana Urosevic - Zurich, CH
Herbert Slade - Woodbury MN, US
John Stolpa - St. Paul MN, US
Mirjana Urosevic - Zurich, CH
Assignee:
3M Innovative Properties Company
International Classification:
A61K031/4745
US Classification:
514/292000, 514/301000, 514/302000, 514/303000
Abstract:
The present invention provides compositions and method for increasing expression of opioid receptors. Generally, the compositions include and opioid receptor inducing compound and, optionally, an opioid receptor ligand. Generally, the methods include contacting a cell with an amount of an opioid receptor inducing compound effective for inducing expression of the opioid receptor and, optionally, contacting the cell with an opioid receptor ligand.